Title : Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.

Pub. Date : 2002

PMID : 12421112






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In well designed studies in patients with mild to moderate hypertension, combinations of the sustained-release (SR) formulation of the nondihydropyridine calcium channel antagonist verapamil 120 to 240 mg/day and the ACE inhibitor trandolapril 0.5 to 8 mg/day were significantly more effective in reducing sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline than placebo. trandolapril angiotensin I converting enzyme Homo sapiens